摘要
目的 观察阿立哌唑联合认知行为治疗慢性精神分裂症的临床效果,为精神科治疗工作提供参考。方法 选取2019年9月—2020年8月山东省临沂市精神卫生中心精神科收治的慢性精神分裂症患者84例,以随机数字表法分为观察组和对照组,每组42例。对照组患者给予阿立哌唑治疗,观察组患者则在对照组基础上实施认知行为治疗,2组均治疗8周进行疗效评价。比较2组患者治疗效果,治疗前后精神状况、认知功能、生活质量评分及不良反应。结果 观察组患者治疗总有效率为95.24%,高于对照组的78.57%(χ^(2)=5.126,P=0.024)。治疗8周后,2组患者阳性与阴性症状量表(PANSS)中阳性症状、阴性症状评分较治疗前均明显降低,且观察组低于对照组(P<0.05或P<0.01);观察组患者威斯康辛卡片分类测验(WCST)中总正确数、完成分类数高于对照组及治疗前,随机错误数、持续错误数低于对照组及治疗前(P<0.05或P<0.01);2组患者精神分裂症生活质量量表(SQLS)评分较治疗前降低,且观察组低于对照组(P均<0.01)。观察组与对照组不良反应总发生率比较差异无统计学意义(11.90%vs. 9.52%,χ^(2)=0.124,P=0.724)。结论 阿立哌唑联合认知行为治疗慢性精神分裂症效果好,有助于改善患者症状、认知功能与生活质量,且患者用药安全性高。
Objective To observe the clinical effect of aripiprazole combined with cognitive behavior therapy in the treatment of chronic schizophrenia,and provide reference for psychiatric treatment.Methods From September 2019 to August 2020,84 patients with chronic schizophrenia admitted to the department of psychiatry of Linyi Mental Health Center were selected,and randomly divided into an observation group and a control group by random number table method,with 42 cases in each group.The control group patients were treated with aripiprazole,while the observation group patients received cognitive behavior therapy on the basis of the control group.Both groups were treated for 8 weeks for efficacy evaluation.The treatment efficacy,mental status,cognitive function,quality of life scores and adverse reactions of the two groups were compared before and after treatment.Results The total effective rate in the observation group was 95.24%,higher than 78.57%in the control group(χ^(2)=5.126,P=0.024).After 8 weeks of treatment,the positive and negative symptom scores on the positive and negative symptom scale(PANSS)in both groups of patients were significantly reduced compared to before treatment,and the observation group were lower than the control group(P<0.05 or P<0.01);The total correct number and categories completed number in the Wisconsin card sorting test(WCST)of patients in the observation group were higher than those in the control group and before treatment,while the scores of random errors and persistent errors were lower than those in the control group and before treatment(P<0.05 or P<0.01);The schizophrenia quality of life scale(SQLS)scores of two groups of patients with schizophrenia decreased compared to before treatment,and the observation group was lower than the control group(all P<0.01).There was no statistically significant difference in the total incidence of adverse reactions between the observation group and the control group(11.90%vs.9.52%,χ^(2)=0.124,P=0.724).Conclusion Aripiprazole combined with cognitive behavior therapy is effective in the treatment of chronic schizophrenia,helping to improve the symptoms,cognitive function and quality of life,and patients with high medication safety.
作者
许亚琼
XU Yaqiong(Department of Psychiatry,Linyi Mental Health Center,Shandong Province,Linyi 276005,China)
出处
《临床合理用药杂志》
2024年第1期13-15,21,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
慢性精神分裂症
阿立哌唑
认知行为
认知功能
生活质量
Chronic schizophrenia
Aripiprazole
Cognitive behavior therapy
Cognitive function
Quality of life
